PHASE I/II TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILD

$0M01FY2000RRNIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications & trials

Paper 38991492 Paper 38278947 Paper 37292813 Paper 36224717 Paper 35486388 Paper 34320286 Paper 33915104 Paper 33653609 Paper 33623667 Paper 33609516 Paper 33479058 Paper 33400972 Paper 33268039 Paper 33136663 Paper 33071178 Paper 32928740 Paper 32888696 Paper 32888689 Paper 32853667 Paper 32562585 Paper 32064729 Paper 31960361 Paper 31886931 Paper 31685489 Paper 31676897 Paper 31513074 Paper 31418516 Paper 31278867 Paper 31167889 Paper 31118516 Paper 30967435 Paper 30522790 Paper 30455329 Paper 29980432 Paper 29936086 Paper 29758564 Paper 29697830 Paper 29427697 Paper 29398050 Paper 29246363 Paper 29157731 Paper 28817419 Paper 28664624 Paper 28588146 Paper 28554178 Paper 28378429 Paper 28188747 Paper 28095749 Paper 27873436 Paper 27839922 Paper 27804265 Paper 27803118 Paper 27603898 Paper 27503277 Paper 27196946 Paper 27190099 Paper 27161901 Paper 27133451 Paper 27099615 Paper 27057209 Paper 26994128 Paper 26866831 Paper 26714848 Paper 26628417 Paper 26616842 Paper 26577415 Paper 26561381 Paper 26537182 Paper 26531295 Paper 26370400 Paper 26236558 Paper 26115542 Paper 26080650 Paper 26025727 Paper 25784663 Paper 25714677 Paper 25705568 Paper 25702853 Paper 25690268 Paper 25635587 Paper 25611822 Paper 25556331 Paper 25444003 Paper 25157095 Paper 25117987 Paper 25099744 Paper 25015575 Paper 24948348 Paper 24913103 Paper 24865480 Paper 24815959 Paper 24811327 Paper 24698216 Paper 24685959 Paper 24652057 Paper 24613131 Paper 24582483 Paper 24582008 Paper 24576856 Paper 24480604

Abstract

This multicenter phase I/II open label study is to be performed in two stages sponsored by the ACTG. Part A will determine the maximally tolerated dose of rIL-2. Part B will treat 15 subjects with the MTD for 5 days every 8 weeks for 3 cycles. The primary objective is to determine the safety of rIL-2 when given to a larger number of children. Secondary objectives are to determine the effects of CD4 cell counts, viral load, and other immumnologic markers.

View original record on NIH RePORTER →